Repeated transvaginal natural orifice transluminal endoscopic surgery: An initial Chinese experience
Journal of Obstetrics and Gynaecology Research · 2023
DOI: 10.1111/jog.15757 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2023. Verfasst von Dan Feng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of Chi…. Hauptthemen laut MEDLINE: Natural Orifice Endoscopic Surgery, Pregnancy, Ectopic, Postoperative Complications, Reoperation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Chengdu High-level Key Clinical Specialty Construction Project, Chengdu Municipal Health Commission Project, Fifth Round of Chengdu Municipal Science and Technology Research Program.
Abstract (Originalsprache)
Aims
To investigate the perioperative outcomes and sexual function of patients undergoing repeated transvaginal natural orifice transluminal endoscopic surgery (vNOTES).
Methods
We retrieved the records of patients who underwent vNOTES twice at our institute between April 2019 and December 2022 and analyzed their baseline information and perioperative complications, and compared the pre‐ and postoperative sexual function of both vNOTES.
Results
Patients' mean age and body mass index were 29.00 ± 3.59 and 30.4 ± 4.00 years and 21.89 ± 3.69 and 22.76 ± 3.88 kg/m 2 , respectively, when receiving the first and second vNOTES. Ectopic pregnancy was the most frequent indication for vNOTES, with 7 cases in the first vNOTES and 11 cases in repeated vNOTES. The interval between the two vNOTESs ranged from 9 days to 38 months. The operation duration (63.33 ± 13.71 vs. 67.33 ± 22.51 min, p = 0.723), intraoperative estimated blood loss (32.00 ± 20.42 vs. 30.00 ± 9.26 mL, p = 0.429), and duration of postoperative hospital stay (2.20 ± 0.56 vs. 2.40 ± 0.51 days, p = 0.082) of both vNOTESs were comparable. No significant differences were found in any of the domains in the comparison of pre‐first and post‐first vNOTES, pre‐second and post‐second vNOTES, and pre‐first and post‐second vNOTES female sexual function index. None of the patients delivered after the second vNOTES.
Conclusion
Repeated vNOTES is safe and feasible. No significant change in the patients' sexual function was found in our cohort after the first and second vNOTES.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- Medical Administrative Department, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
ORCID-Profile: Dan Feng, Tianjiao Liu, Xin Li, Li He
Förderung
- Chengdu High-level Key Clinical Specialty Construction Project
- Chengdu Municipal Health Commission Project
- Fifth Round of Chengdu Municipal Science and Technology Research Program
- Japan China Sasakawa Medical Fellowship Program
- Chengdu Municipal Medical Research Project in 2023
Zitieren
APA
Feng, D., Liu, T., Li, X., Peng, J., Huang, L., & He, L. (2023). Repeated transvaginal natural orifice transluminal endoscopic surgery: An initial Chinese experience. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.15757
Vancouver
Feng D, Liu T, Li X, Peng J, Huang L, He L. Repeated transvaginal natural orifice transluminal endoscopic surgery: An initial Chinese experience. Journal of Obstetrics and Gynaecology Research. 2023. doi:10.1111/jog.15757
BibTeX
@article{Feng2023,
author = {Feng, Dan and Liu, Tianjiao and Li, Xin and Peng, Jieru and Huang, Lu and He, Li},
title = {Repeated transvaginal natural orifice transluminal endoscopic surgery: An initial Chinese experience},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2023},
doi = {10.1111/jog.15757}
}
EUVIMED